The effect of acetazolamide on lithium-induced nephrogenic diabetes insipidus in patients with an affective disorder: a pilot study
- Conditions
- excessive urine production due to a diminished concentrating ability of the kidney as a result of the use of lithiumlithium-induced nephrogenic diabetes insipidus10038430
- Registration Number
- NL-OMON35668
- Lead Sponsor
- niversitair Medisch Centrum Sint Radboud
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 6
sex: men and women
age: 18 years and older
stable patients treated with lithium for an affective disorder
moderate to severe lithium-induced nephrogenic diabetes insipidus (max. urinary osmolality >150 and <600 mOsm/kg)
pregnancy
diabetes mellitus
underlying renal disorders
significant cardiac/pulmonary comorbidity
heart rhythm disorders
pre-existent side effects of lithium treatment
treatment with hydrochlorothiazide or amiloride in the preceding 2 weeks
concomittant treatment with other diuretics
hypotension (systolic blood pressure <100 mm Hg)
renal insufficiency
hypo/hyperkalemia
hypercalcaemia
hypo/hyperthyroidism
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Primary study parameters:<br /><br>- maximal urine volume reduction after stimulation with dDAVP<br /><br>- maximal urine osmolality after stimulation with dDAVP<br /><br>Both parameters will be evaluated 7 days before and 28 days after the start of<br /><br>treatment with acetazolamide. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary study parameters:<br /><br>- subjective symptoms (frequency of micturition)<br /><br>- vital signs (body weight and blood pressure)<br /><br>- blood levels of sodium, potassium, chloride, bicarbonate, lithium,<br /><br>creatinine, haemoglobin and osmolality-<br /><br>- urine levels of sodium, potassium, osmolality, urea and creatinine in morning<br /><br>spot urine samples<br /><br>- side effects of acetazolamide treatment<br /><br>- psychiatric outcome<br /><br>All parameters will be evaluated 7 days before and on day 0, 7, 14, 21, 28 and<br /><br>42 after the start of treatment with acetazolamide. </p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.